-
1
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
Druker BJ, Tamura S, Buchduner E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
-
(1996)
Nat Med
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchduner, E.3
-
2
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
DOI 10.1126/science.1062538
-
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
-
(2001)
Science
, vol.293
, Issue.5531
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Nagesh, R.P.6
Sawyers, C.L.7
-
3
-
-
54349089682
-
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
-
Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-13.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4806-4813
-
-
Khorashad, J.S.1
De Lavallade, H.2
Apperley, J.F.3
-
4
-
-
77953790762
-
Discovery of 3-[2-(imidazo[1,2b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4- [(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant
-
Huang W-S, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53:4701-19.
-
(2010)
J Med Chem
, vol.53
, pp. 4701-4719
-
-
Huang, W.-S.1
Metcalf, C.A.2
Sundaramoorthi, R.3
-
5
-
-
70350507997
-
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
-
O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12.
-
(2009)
Cancer Cell
, vol.16
, pp. 401-412
-
-
O'Hare, T.1
Shakespeare, W.C.2
Zhu, X.3
-
6
-
-
84870012939
-
Ponatinib in refractory Philadelphia chromosome - Positive leukemias
-
Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome - positive leukemias. N Engl J Med 2012;367:2075-88.
-
(2012)
N Engl J Med
, vol.367
, pp. 2075-2088
-
-
Cortes, J.E.1
Kantarjian, H.2
Shah, N.P.3
-
7
-
-
85031175535
-
PACE: A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315 mutation
-
Presented at the abstract
-
Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. PACE: a pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315 mutation. Presented at the 17th Congress of the European Hematology Association, Amsterdam, June 14-17, 2012. abstract.
-
17th Congress of the European Hematology Association, Amsterdam, June 14-17, 2012
-
-
Cortes, J.E.1
Kim, D.-W.2
Pinilla-Ibarz, J.3
-
8
-
-
79958760963
-
Potent activity of ponatinib in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies
-
Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011;10:1028-35.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1028-1035
-
-
Gozgit, J.M.1
Wong, M.J.2
Wardwell, S.3
|